Scientists sue NIH and HHS over terminated brain research grants

People in a historically Black corner of Pittsburgh took memory tests, tracked their sleep and blood pressure and shared stories of their past to help scientists unravel risks for Alzheimer’s disease. They may never get answers.

The study was among broader research into why Black Americans are twice as likely as their white peers to develop Alzheimer’s, and the Trump administration abruptly halted it in its final stretch, according to the researchers who ran it. The study had been near completion in its fifth and final year when the National Institutes of Health stripped its funding last year, the researchers said, on the grounds that it was “not science.” That decision came despite a rigorous review and vetting from a community advisory board, they said.

Researchers say the move not only wasted more than $8 million in taxpayer money already spent but also struck at the hard-earned trust of anxious participants who will not learn whether their brain tests showed signs of trouble.

Roderick Blair, 70, who had taken part in the study for four years, described what he expects the neighborhood will conclude. “The community will look like, ‘Oh, they came in here, they took all our stuff, they checked us out. Now they’re gonna leave us hanging,’” he said.

Trust in U.S. health institutions has long been strained in the Black community, stemming from long-standing racial health inequities, unequal access to care and bias within the nation’s medical system. The legacy of the Tuskegee study, which withheld treatment from Black men who had been infected with syphilis in the 1930s, still casts a shadow.

The Pittsburgh study overcame that mistrust, according to La’Vette Wagner, the study’s field coordinator. Getting people involved in the city’s Hill and Homewood communities helped get residents talking about memory loss, dementia and Alzheimer’s, and helped challenge misconceptions about the disease, she said.

Families who once dismissed memory loss as depression began asking about dementia, Wagner said, and people outside the study called her to ask whether family members could join. More than half of Black Americans, or 55%, believe that a significant loss of memory or cognitive abilities is a natural part of aging rather than disease, according to the Alzheimer’s Association.

As Blair put it: “You start forgetting things and you start to wonder, do you have Alzheimer’s? You wonder, do you have dementia?”

Wagner rejected the characterization behind the termination. “It wasn’t a Black study or a DEI study,” she said. “It was something that was happening that was real.”

Similar terminations happened around the country. Negar Fani, a neuropsychologist at Emory University in Atlanta, was two years into a five-year, $2.9 million project on how daily experiences of racial discrimination affect the brain and body of Black Americans when NIH terminated it in July. Fani’s grant was terminated for being “not scientific” and “subjective,” she said, after the study had been approved and had enrolled 66 of the 220 people it sought.

“It’s simply brain science research,” she said. Fani is now trying to find the roughly $2.3 million she needs to complete the study, while she and her team try to explain the situation to participants who feel abandoned. “It takes a lot to restore trust with the Black community, who has experienced so many different betrayals,” she said.

In Pittsburgh, study lead researcher Andrea Rosso is one of numerous scientists in a recently filed lawsuit against NIH and its parent Department of Health and Human Services, one of a growing body of legal actions as the administration continues to hunt for and halt medical grants whose descriptions include the words “disparities,” “minority” and “racial.” Ann Cohen, a director of Pittsburgh’s Alzheimer’s Disease Research Center, also is part of that lawsuit after her separate, complementary study of Alzheimer’s risk was halted, following $5.2 million spent over three years. She faces a further ethics question: what to do with blood samples collected from participants.

“You lose trust a hell of a lot faster than you build it,” Cohen said.

An HHS spokesperson defended the agency’s direction. “Massive amounts of DEI grants have failed to translate into better health outcomes for minority populations,” the spokesperson said. “Following President Trump’s directives, NIH is shifting money into rigorous research that will help Americans — including minority populations — live longer, healthier lives.”

This year, NIH has awarded 2,000 fewer grants for multiyear studies, worth a total of $200 million less compared with 2025, according to an Association of American Medical Colleges report.

“It’s unprecedented. Many of the decisions are based on political biases and based on what politicians think is valuable rather than peer review processes, evidence-based decisions about where to invest our research dollars,” said Jill Rosenthal, director of public health policy at the Center for American Progress. “We’re wasting resources, we’re wasting the opportunity to identify cures for diseases,” she said.

Researchers in Pittsburgh are especially concerned that promises made to the community will remain unfulfilled. The study, 15 years in the making, would have helped identify participants at higher risk for Alzheimer’s, and for potential doctor’s visits and care. Now, Wagner said, the findings are “stuck on a shelf,” and worse, more than a decade of trust built with study participants has been breached.

Blair said restoring that trust in his community will be an uphill battle. “It’s going to take years to reestablish something that was moving pretty good,” he said.